FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT	OF CHANGES	S IN BENEFI	CIAL OWN	ERSHIP

OMB APP	ROVAL
OMB Number:	3235-0287
Estimated average b	ourden
hours per response.	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Swisher Daniel N JR					2. Issuer Name and Ticker or Trading Symbol CORCEPT THERAPEUTICS INC [CORT]								(Che	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner							
(Last)	•	,	(Middle)			3. Date of Earliest Transaction (Month/Day/Year) 11/01/2023									Officer below)	(give title		Other (s below)	specify		
C/O CORCEPT THERAPEUTICS INCORPORATED			4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)								Line	6. Individual or Joint/Group Filing (Check Applicable Line)								
149 COMMONWEALTH DRIVE					-											X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(Street) MENLO	PARK (CA	94025		Rı	Rule 10b5-1(c) Transaction Indication															
(City)	(State)	(Zip)		X	Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.															
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																				
1. Title of Security (Instr. 3) 2. Transar Date (Month/D				Execution D		on Date,	Code (In			on Disposed Of		ties Acquired (A) I Of (D) (Instr. 3, 4			es ally Following	Form (D) or	: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership			
										ode \	,	Amount	(A) (D)	or F	Price	Reporte Transac (Instr. 3	tion(s)			(Instr. 4)	
Common Stock 11/01/2					1/2023	2023		1	M		2,200) A		\$5.86		,200		D			
Common Stock 11/01/			1/2023	/2023			S	(1)		2,200	D \$27		\$27.96	96 0		D					
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																					
Derivative Conversion Date Execution Date, T Security or Exercise (Month/Day/Year) if any				ransaction of ode (Instr. Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		curity	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)					
					Code	v	(A)	(D)	Date Exerc	cisable		xpiration ate	Title	or Nu of	mber ares						
Stock option (right to buy)	\$5.86	11/01/2023			М			2,200	((2)	0	7/21/2026	Common Stock	2,	200	\$0	17,750		D		

Explanation of Responses:

- 1. The transaction was made pursuant to a 10b5-1 plan in effect at the time of this transaction.
- 2. Fully exercisable.

Remarks:

The power of attorney under which this form was signed is on file with the Commission.

/s/ Joseph Douglas Lyon, as attorney-in-fact for Daniel N. 11/03/2023 Swisher, Jr.

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

 $Persons \ who \ respond \ to \ the \ collection \ of \ information \ contained \ in \ this \ form \ are \ not \ required \ to \ respond \ unless \ the \ form \ displays \ a \ currently \ valid \ OMB \ Number.$